Significant advances have been made in the treatment of prostate cancer in recent years, significantly improving the prognosis of patients with severe disease. However, it was unclear whether any of the new treatment options are superior to the others and what the cost-benefit ratio is. In its newly published report, the Swiss Medical Board gives all options a positive rating.